Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Topotecan or treosulfan—that is the question

Nature Reviews Clinical Oncology volume 6, pages 559–560 (2009)Cite this article

Meier and coauthors found that topotecan improved progression-free and overall survival compared with treosulfan in patients with recurrent ovarian cancer following platinum and taxane-based therapy. Although these results are promising, the optimum treatment strategy for patients with recurrent ovarian cancer still remains to be determined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Covens, A. et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol. Oncol. 85, 71–80 (2002).

    Article  CAS  Google Scholar 

  2. Elit, L. et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109, 692–702 (2007).

    Article  CAS  Google Scholar 

  3. Markman, M. Pharmaceutical management of ovarian cancer: current status. Drugs 68, 771–789 (2008).

    Article  CAS  Google Scholar 

  4. Pujade-Lauraine, E. et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) [abstract]. ASCO Meeting Abstracts 27, LBA5509 (2009).

    Google Scholar 

  5. Vergote, I. et al. Single agent, canfosfamide vs pegylated doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results [abstract]. ASCO Meeting Abstracts 25, LBA5528 (2007).

    Google Scholar 

  6. Meier, W. et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol. Oncol. 114, 199–205 (2009).

    Article  CAS  Google Scholar 

  7. Hennessy, B. & Markman, M. Development of novel agents for ovarian cancer. Update Cancer Ther. 3, 119–132 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Topotecan or treosulfan—that is the question. Nat Rev Clin Oncol 6, 559–560 (2009). https://doi.org/10.1038/nrclinonc.2009.144

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.144

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing